Form 4: Castle Biosciences Executive Sells Shares
Insider Transaction (Form 4)
Derek J Maetzold, Pres. & Chief Exec. Officer and a Director of Castle Biosciences Inc, sold 4,172 shares of common stock on July 14, 2026 for $22.92 per share.
Summary
- Option exercise/conversion: acquired 550 Common Stock at $2.39 ($1,314) on July 14, 2026; holds 22,029 after (Direct).
- Open-market sale: disposed of 550 Common Stock at $22.92 ($12,606) on July 14, 2026; holds 21,479 after (Direct).
- Open-market sale: disposed of 1,357 Common Stock at $22.92 ($31,102) on July 14, 2026; holds 39,353 after (Indirect).
- Open-market sale: disposed of 1,153 Common Stock at $22.92 ($26,427) on July 14, 2026; holds 33,449 after (Indirect).
- Open-market sale: disposed of 278 Common Stock at $22.92 ($6,372) on July 14, 2026; holds 12,090 after (Indirect).
- Open-market sale: disposed of 278 Common Stock at $22.92 ($6,372) on July 14, 2026; holds 12,090 after (Indirect).
- Open-market sale: disposed of 278 Common Stock at $22.92 ($6,372) on July 14, 2026; holds 12,090 after (Indirect).
- Open-market sale: disposed of 278 Common Stock at $22.92 ($6,372) on July 14, 2026; holds 12,090 after (Indirect).
- Option exercise/conversion: disposed of 550 Stock option (right to buy) on July 14, 2026; holds 85,117 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $95,622 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Derek J Maetzold — Director, Officer (Pres. & Chief Exec. Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-14 | Option exercise/conversion | Common Stock | 550 | $2 | $1.3K | 22,029 |
| 2026-07-14 | Open-market sale | Common Stock | 550 | $23 | $12.6K | 21,479 |
| 2026-07-14 | Open-market sale | Common Stock | 1,357 | $23 | $31.1K | 39,353 |
| 2026-07-14 | Open-market sale | Common Stock | 1,153 | $23 | $26.4K | 33,449 |
| 2026-07-14 | Open-market sale | Common Stock | 278 | $23 | $6.4K | 12,090 |
| 2026-07-14 | Open-market sale | Common Stock | 278 | $23 | $6.4K | 12,090 |
| 2026-07-14 | Open-market sale | Common Stock | 278 | $23 | $6.4K | 12,090 |
| 2026-07-14 | Open-market sale | Common Stock | 278 | $23 | $6.4K | 12,090 |
| 2026-07-14 | Option exercise/conversion | Stock option (right to buy) | 550 | — | — | 85,117 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-14 | Option exercise/conversion (550 shares) |
| 2026-07-14 | Open-market sale (550 shares) |
| 2026-07-14 | Open-market sale (1,357 shares) |
| 2026-07-14 | Open-market sale (1,153 shares) |
| 2026-07-14 | Open-market sale (278 shares) |
| 2026-07-14 | Open-market sale (278 shares) |
| 2026-07-14 | Open-market sale (278 shares) |
| 2026-07-14 | Open-market sale (278 shares) |
| 2026-07-14 | Option exercise/conversion (550 shares) |
Keywords
insider transaction, Form 4, CSTL, CASTLE BIOSCIENCES INC, bearish, Derek J Maetzold
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.